# Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer

> **NCT02767752** · PHASE2 · TERMINATED · sponsor: **Herlev Hospital** · enrollment: 21 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** T-ChOS
- **DRUG:** Gemcitabine
- **DIETARY_SUPPLEMENT:** Placebo
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02767752
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Poor accrual and change of SOC (FOLFIRINOX in adjuvant setting)
- **Last updated:** 2018-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02767752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02767752, "Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02767752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*